ROCHE HOLDING AG
COVID-19 Infections and Vaccinations in the P783 (ePoster)
Swiss Multiple Sclerosis Cohort Study
------------------------------------------------------------ ----------------
Pregnancy and Infant Outcomes in Women Receiving P641 (ePoster)
Ocrelizumab for the Treatment of Multiple
Sclerosis
------------------------------------------------------------ ----------------
Rationale and Design of a Phase 4 Study Exploring P655 (ePoster)
B-cell Levels and Immune Responses in Infants
Born to Women with MS Who Were Exposed to
Ocrelizumab up to 6 Months Before or During
the First Trimester of Pregnancy (the MINORE
Study)
------------------------------------------------------------ ----------------
B-cell Levels and Immunity in Breastfed Infants P686 (ePoster)
of Women with MS Treated with Ocrelizumab:
Design of a Phase 4 Study (SOPRANINO)
------------------------------------------------------------ ----------------
Real World Experience with Ocrelizumab in P117 (ePoster)
Patients with Primary Progressive Multiple
Sclerosis: Insights From the German NeuroTransData
Registry
------------------------------------------------------------ ----------------
CELLO: A Phase IV, Multicenter, Randomized, P702 (ePoster)
Double-blind, Placebo-controlled Study Assessing
Efficacy of Ocrelizumab in Radiologically
Isolated Syndrome
------------------------------------------------------------ ----------------
Impact of the COVID-19 Pandemic on Healthcare P830 (ePoster)
Utilisation in US People Living with MS: An
Analysis of the FlywheelMS Cohort
------------ ------------------------------------------------------------ ----------------
Floodlight A Patient-focused Qualitative Study to Support P309 (ePoster)
for MS Content Validity of Digital Performance Assessments
in MS
------------ ------------------------------------------------------------ ----------------
Novel Smartphone Sensor-based Scores for Remote P306 (ePoster)
Measurement of Gait and Hand Function Impairment
in People with MS
------------ ------------------------------------------------------------ ----------------
A Digital Remote Monitoring Assessment for P303 (ePoster)
Measuring Impairment in Information Processing
Speed in People with MS
------------------------------------------------------------ ----------------
Establishing Consensus Definitions of Smartphone-based P308 (ePoster)
Digital Outcome Measurements in Multiple Sclerosis
------------------------------------------------------------ ----------------
The Importance of Quality Checks for Digital P305 (ePoster)
Health Studies Using Remote Unsupervised Assessments
to Study Functional Impairment in MS
------------ ------------------------------------------------------------ ----------------
Fenebrutinib Fenebrutinib Reduces Disease Activity in a P680 (ePoster)
for MS Mouse Model of Inflammatory Multiple Sclerosis,
Which is Associated with Reduced Microglial
Activation
------------ ------------------------------------------------------------ ----------------
ENSPRYNG Long-Term Safety of Satralizumab in NMOSD: P023 (ePoster)
for NMOSD Results From the Open-Label Extension Periods
of SAkuraSky and SAkuraStar
------------ ------------------------------------------------------------ ----------------
Long-term Efficacy of Satralizumab in Aquaporin-4-IgG- P024 (ePoster)
Seropositive NMOSD: Results From the Open-Label
Extension Periods of SAkuraSky and SAkuraStar
------------ ------------------------------------------------------------ ----------------
SAkuraBONSAI: A Prospective, Open-Label Study P039 (ePoster)
of Satralizumab Investigating Novel Imaging,
Biomarker, and Clinical Outcomes in Patients
with AQP4-IgG Seropositive NMOSD
------------------------------------------------------------ ----------------
Exploring Steroid Tapering in NMOSD Patients P038 (ePoster)
Treated with Satralizumab in the Open-Label
Extension Period of SAkuraSky: a Case Series
------------------------------------------------------------ ----------------
Characterization of a Neuromyelitis Optica P321 (ePoster)
Mice Model Induced
by AQP4 Peptide Immunization
------------------------------------------------------------ ----------------
Novel Assessment of Disability vs Cognition P031 (ePoster)
and Pain in NMOSD: a CIRCLES Cohort Study
------------------------------------------------------------ ----------------
Novel Disability Assessment of NMOSD Derived P030 (ePoster)
From the CIRCLES Experience
------------------------------------------------------------ ----------------
Using Cognitive Interviews to Develop a Conceptual P049 (ePoster)
Claims-Based Algorithm to Identify Patients
with NMSOD
------------------------------------------------------------ ----------------
Comparing Healthcare Resource Utilization P041 (ePoster)
and Costs of Active and Inactive Periods in
NMOSD
------------------------------------------------------------ ----------------
Evaluating the Economic and Healthcare Resource P045 (ePoster)
Burden Posed by NMOSD
------------ ------------------------------------------------------------ ----------------
Multinomial Modeling Reveals Insights Into P984 (ePoster)
Disability in NMOSD:
A CIRCLES Cohort Analysis
------------ ------------------------------------------------------------ ----------------
About OCREVUS(R) (ocrelizumab)
OCREVUS is the first and only therapy approved for both RMS (including RRMS and active, or relapsing, secondary progressive MS [SPMS], in addition to clinically isolated syndrome [CIS] in the U.S.) and PPMS. OCREVUS is a humanised monoclonal antibody designed to target CD20-positive B cells, a specific type of immune cell thought to be a key contributor to myelin (nerve cell insulation and support) and axonal (nerve cell) damage. This nerve cell damage can lead to disability in people with MS. Based on preclinical studies, OCREVUS binds to CD20 cell surface proteins expressed on certain B cells, but not on stem cells or plasma cells, suggesting that important functions of the immune system may be preserved. OCREVUS is administered by intravenous infusion every six months. The initial dose is given as two 300 mg infusions given two weeks apart. Subsequent doses are given as single 600 mg infusions.
About ENSPRYNG(R) (satralizumab)
ENSPRYNG, which was designed by Chugai, a member of the Roche Group, is a humanised monoclonal antibody that targets interleukin-6 (IL-6) receptor activity. The cytokine IL-6 is believed to be a key driver in NMOSD disease processes, triggering the inflammation cascade and leading to damage and disability. ENSPRYNG was designed using novel recycling antibody technology. When compared to conventional antibodies, ENSPRYNG's recycling antibody technology enables the medicine to remain in the bloodstream for a longer period of time and bind repeatedly to its target (the IL-6 receptor) - maximally sustaining IL-6 suppression in a chronic disease like NMOSD and enabling subcutaneous dosing every four weeks.
Positive Phase III results for ENSPRYNG, as both monotherapy and in combination with baseline immunosuppressive therapy, suggest that IL-6 inhibition is an effective therapeutic approach for NMOSD. The Phase III clinical development programme for ENSPRYNG includes two studies: SAkuraStar and SAkuraSky.
ENSPRYNG is currently approved in 58 countries, including the United States, Canada, Japan, South Korea and the European Union.
ENSPRYNG has been designated as an orphan drug in the United States, Europe, Japan and Russia. In addition, it was granted Breakthrough Therapy Designation for the treatment of NMOSD by the FDA in December 2018, which is given to treatments that may demonstrate substantial improvement over other available options.
About Roche in neuroscience
Neuroscience is a major focus of research and development at Roche. Our goal is to pursue groundbreaking science to develop new treatments that help improve the lives of people with chronic and potentially devastating diseases.
Roche is investigating more than a dozen medicines for neurological disorders, including multiple sclerosis, Alzheimer's disease, Huntington's disease, Parkinson's disease, Duchenne muscular dystrophy and autism spectrum disorder. Together with our partners, we are committed to pushing the boundaries of scientific understanding to solve some of the most difficult challenges in neuroscience today.
About Roche
(MORE TO FOLLOW) Dow Jones Newswires
October 05, 2021 01:00 ET (05:00 GMT)
